203 related articles for article (PubMed ID: 24218548)
21. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
22. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
[TBL] [Abstract][Full Text] [Related]
23. [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
Li ZW; Yang ZL; Feng HL; Bian XC; Liu YY; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):330-5. PubMed ID: 24004591
[TBL] [Abstract][Full Text] [Related]
24. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
25. Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.
Alcolea MP; Casado P; Rodríguez-Prados JC; Vanhaesebroeck B; Cutillas PR
Mol Cell Proteomics; 2012 Aug; 11(8):453-66. PubMed ID: 22547687
[TBL] [Abstract][Full Text] [Related]
26. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
27. ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage.
Bensimon A; Schmidt A; Ziv Y; Elkon R; Wang SY; Chen DJ; Aebersold R; Shiloh Y
Sci Signal; 2010 Dec; 3(151):rs3. PubMed ID: 21139141
[TBL] [Abstract][Full Text] [Related]
28. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
29. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
30. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
[TBL] [Abstract][Full Text] [Related]
31. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
32. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
33. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
34. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
35. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Hatzivassiliou G; Haling JR; Chen H; Song K; Price S; Heald R; Hewitt JF; Zak M; Peck A; Orr C; Merchant M; Hoeflich KP; Chan J; Luoh SM; Anderson DJ; Ludlam MJ; Wiesmann C; Ultsch M; Friedman LS; Malek S; Belvin M
Nature; 2013 Sep; 501(7466):232-6. PubMed ID: 23934108
[TBL] [Abstract][Full Text] [Related]
37. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.
Shortt J; Martin BP; Newbold A; Hannan KM; Devlin JR; Baker AJ; Ralli R; Cullinane C; Schmitt CA; Reimann M; Hall MN; Wall M; Hannan RD; Pearson RB; McArthur GA; Johnstone RW
Blood; 2013 Apr; 121(15):2964-74. PubMed ID: 23403624
[TBL] [Abstract][Full Text] [Related]
39. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
40. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival.
Coutant A; Rescan C; Gilot D; Loyer P; Guguen-Guillouzo C; Baffet G
Hepatology; 2002 Nov; 36(5):1079-88. PubMed ID: 12395317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]